Cara taps Korean firm as first licensee for its lead analgesic
This article was originally published in Scrip
Executive Summary
The US venture Cara Therapeutics has struck the first licensing deal for its lead product candidate CR845, allying with Chong Kun Dang Pharmaceutical (CKD) for the development and marketing of the analgesic in South Korea.